Amyloid-β, anxiety, and cognitive decline in preclinical alzheimer disease a multicenter, prospective cohort study

JAMA Psychiatry

Volumn 72, Issue 3, 2015, Pages 284-291

  Pietrzak, Robert H ^a,b   Lim, Yen Ying ^c,d   Neumeister, Alexander ^e   Ames, David ^f,g   Ellis, Kathryn A ^c   Harrington, Karra ^c   Lautenschlager, Nicola T ^f,g   Restrepo, Carolina ^c   Martins, Ralph N ^h   Masters, Colin L ^c   Villemagne, Victor L ^c,i   Rowe, Christopher C ^c,i   Maruff, Paul ^c,j  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BROWN UNIVERSITY   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Department of Psychiatry   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h EDITH COWAN UNIVERSITY   (Australia)

ⁱ AUSTIN HEALTH   (Australia)

^j Cogstate Ltd ^*  (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; FLORBETAPIR F 18; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ANXIETY; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DEPTH PERCEPTION; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GENOTYPE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; VERBAL MEMORY; VISUAL MEMORY; CLINICAL TRIAL; DISEASE COURSE; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRODROMAL SYMPTOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANXIETY; DEPRESSION; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PRODROMAL SYMPTOMS; PROSPECTIVE STUDIES;

EID: 84925378753     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2476     Document Type: Article

References (51)

1. Langbaum JB, Fleisher AS, Chen K, et al. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol. 2013;9(7):371-381.
2. Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis. 2013;33(suppl 1):S405-S416.
3. Chételat G, Villemagne VL, Pike KE, et al; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain. 2011;134(Pt 3):798-807.
4. Doraiswamy PM, Sperling RA, Johnson K, et al; AV45-A11 Study Group. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044-1051.
5. Ellis KA, Lim YY, Harrington K, et al; AIBL Research Group. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β. J Alzheimers Dis. 2013;34(4):861-871.
6. Lim YY, Ellis KA, Pietrzak RH, et al; AIBL Research Group. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79(16):1645-1652.
7. Lim YY, Maruff P, Pietrzak RH, et al; AIBL Research Group. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain. 2014;137(Pt 1):221-231.
8. Lim YY, Maruff P, Pietrzak RH, et al; AIBL Research Group. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease [published online February 28, 2014]. Alzheimers Dement. doi:10.1016/j.jalz.2013.11.005.
9. Villemagne VL, Burnham S, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.
10. Lavretsky H, Siddarth P, Kepe V, et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry. 2009;17(6):493-502.
11. Ramakers IH, Verhey FR, Scheltens P, et al; Alzheimer's Disease Neuroimaging Initiative and DESCRIPA Investigators. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med. 2013; 43(5):911-920.
12. Beaudreau SA, O'Hara R. Late-life anxiety and cognitive impairment: a review. Am J Geriatr Psychiatry. 2008;16(10):790-803.
13. Beaudreau SA, O'Hara R. The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. Psychol Aging. 2009;24(2):507-512.
14. Bierman EJ, Comijs HC, Jonker C, Beekman AT. Effects of anxiety versus depression on cognition in later life. Am J Geriatr Psychiatry. 2005;13(8):686-693.
15. EysenckMW, Derakshan N, Santos R, Calvo MG. Anxiety and cognitive performance: attentional control theory. Emotion. 2007;7(2):336-353.
16. Geda YE, Roberts RO,Mielke MM, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry. 2014;171(5):572-581.
17. Murrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. 2011;96(4):553-563.
18. Yochim BP, Mueller AE, Segal DL. Late life anxiety is associated with decreased memory and executive functioning in community dwelling older adults. J Anxiety Disord. 2013;27(6):567-575.
19. Beaudreau SA, Kaci Fairchild J, Spira AP, Lazzeroni LC, O'Hara R. Neuropsychiatric symptoms, apolipoprotein E gene, and risk of progression to cognitive impairment, no dementia and dementia: the Aging, Demographics, and Memory Study (ADAMS). Int J Geriatr Psychiatry. 2013;28(7):672-680.
20. Gallacher J, Bayer A, FishM, et al. Does anxiety affect risk of dementia? findings from the Caerphilly Prospective Study. Psychosom Med. 2009;71(6):659-666.
21. Potvin O, Forget H, Grenier S, Préville M, Hudon C. Anxiety, depression, and 1-year incident cognitive impairment in community-dwelling older adults. J AmGeriatr Soc. 2011;59(8):1421-1428.
22. Potvin O, Hudon C, Dion M, Grenier S, Préville M. Anxiety disorders, depressive episodes and cognitive impairment no dementia in community-dwelling older men and women. Int J Geriatr Psychiatry. 2011;26(10):1080-1088.
23. Bierman EJ, Comijs HC, Rijmen F, Jonker C, Beekman AT. Anxiety symptoms and cognitive performance in later life: results from the Longitudinal Aging Study Amsterdam. Aging Ment Health. 2008;12(4):517-523.
24. Biringer E, Mykletun A, Dahl AA, et al. The association between depression, anxiety, and cognitive function in the elderly general population: the Hordaland Health Study. Int J Geriatr Psychiatry. 2005;20(10):989-997.
25. Potvin O, Bergua V, Meillon C, et al. State anxiety and cognitive functioning in older adults. Am J Geriatr Psychiatry. 2013;21(9):915-924.
26. van't Veer-Tazelaar PJ, van Marwijk HW, van Oppen P, et al. Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. Arch Gen Psychiatry. 2009;66(3):297-304.
27. van Zoonen K, Buntrock C, Ebert DD, et al. Preventing the onset of major depressive disorder: ameta-analytic review of psychological interventions. Int J Epidemiol. 2014;43(2):318-329.
28. Serfaty MA, Haworth D, Blanchard M, Buszewicz M, Murad S, King M. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled trial. Arch Gen Psychiatry. 2009;66(12):1332-1340.
29. Orgeta V, Qazi A, Spector AE, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014;1:CD009125.
30. Pietrzak RH, Scott JC, Neumeister A, et al; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. Br J Psychiatry. 2014;204:400-401.
31. Ellis KA, Bush AI, Darby D, et al; AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr. 2009;21(4):672-687.
32. Ellis KA, Rainey-Smith SR, Rembach A, Macaulay SL, Villemagne VL; AIBL Research Group. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Int Rev Psychiatry. 2013;25(6):699-710.
33. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
34. Clark CM, Schneider JA, Bedell BJ, et al; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-283.
35. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319-329.
36. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res. 2002;52(2):69-77.
37. Yates PA, Desmond PM, Phal PM, et al; AIBL Research Group. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology. 2014;82(14):1266-1273.
38. Wiederkehr S, Laurin D, Simard M, Verreault R, Lindsay J. Vascular risk factors and cognitive functions in nondemented elderly individuals. J Geriatr Psychiatry Neurol. 2009;22(3):196-206.
39. Crook TH III, Feher EP, Larrabee GJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr. 1992;4(2):165-176.
40. Harrington KD, Lim YY, Ellis KA, et al. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI. Int Psychogeriatr. 2013;25(10):1667-1677.
41. Villain N, Chételat G, Grassiot B, et al; AIBL Research Group. Regional dynamics of amyloid-β deposition in healthy elderly,mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135(pt 7):2126-2139.
42. McEwen BS. Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci U S A. 2012;109(suppl 2):17180-17185.
43. Brureau A, Zussy C, Delair B, et al. Deregulation of hypothalamic-pituitary-adrenal axis functions in an Alzheimer's disease rat model. Neurobiol Aging. 2013;34(5):1426-1439.
44. España J, Giménez-Llort L, Valero J, et al. Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry. 2010;67(6):513-521.
45. HuijbersW, Mormino EC,Wigman SE, et al. Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. J Neurosci. 2014;34(15):5200-5210.
46. Satpute AB, Mumford JA, Naliboff BD, Poldrack RA. Human anterior and posterior hippocampus respond distinctly to state and trait anxiety. Emotion. 2012;12(1):58-68.
47. BoldriniM, Hen R, Underwood MD, et al. Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol Psychiatry. 2012;72(7):562-571.
48. Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology. 2009;34(11):2376-2389.
49. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? a double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007;27(1):67-70.
50. Mowla A, Mosavinasab M, Haghshenas H, Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? a double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007;27(5):484-487.
51. Sheline YI,West T, Yarasheski K, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):236re4.